Back to Top

"One of today's leaders in investor relations and shareholder services"

Tag Archives: MJNA

Kannaway LLC (MJNA)

A Closer Look at Kannaway LLC

Kannaway LLC (MJNA)

We’re always in search of other leaders in the cannabis industry who support and provide products to those who utilize the healing powers of medicinal marijuana and other similar products. Kannaway LLC is a subsidiary of Medical Marijuana, Inc. (MJNA). Kannaway reigns as the first lifestyle network to provide hemp-based botanical products to consumers. Their innovated products supply consumers with access to herbal blends and oils that support health and wellness through natural means.

Who Kannaway Is

Kannaway continuously strives to provide individuals with holistically sound choices for supplements and skincare products. They’re the first direct marketing company of its kind to give consumers access to legal hemp products. In 2014, the Academy of Multi-level Marketing awarded them with the title of “Start-up of the Year,” which was attributed to their rapid growth and solid foundation. Today, they’re continuing to guide the path of the cannabis market in the …

Continue Reading

Posted in Articles| Tagged , , , , |

Medical Marijuana, Inc. Major Investment AXIM Biotech Moves Forward With Development Of MedChew Rx Pharmaceutical Chewing Gum

SAN DIEGO, May 3, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc.’s (AXIM® Biotech) (OTC: AXIM) product development partner Quay Pharmaceuticals Ltd. (“Quay Pharma”) has obtained the relevant licenses from the British Home Office to import and work with the controlled drugs that are required to continue the development of AXIM MedChew Rx® pharmaceutical chewing gum products.

MedChew Rx® is being developed as a pharmaceutical drug to treat pain and spasticity associated with multiple sclerosis (MS). It is formulated with 5 mg of cannabidiol (CBD) and 5 mg of tetrahydrocannabinol (THC).

The value of the MS treatment market is estimated to reach $20 billion by 2024, according to research firm GlobalData. This growth is primarily driven by the continued development of new products and an increase in diagnosis rates across …

Continue Reading

Posted in Client News| Tagged , , , |
Medical Marijuana (MJNA)

MJNA Financial Numbers Tell Story of a Company on the Rise

Medical Marijuana (MJNA)

Medical Marijuana, Inc., traded publicly under the ticker symbol MJNA, has made history as the world’s first cannabis company to be publicly traded in the United States. 2016 was a big year for the company with record growth, international import permissions being granted by multiple government agencies, and promising clinical trial results from MJNA’s revolutionary product lines.

Financial Growth

In the last quarter of 2016, Medical Marijuana, Inc.’s revenue increased by 66 percent compared to the first quarter of 2016. The company also had a Net Comprehensive Income increase of 731 percent compared to the same figure in 2015. Finishing out 2016 with a net income of greater than $8 million, the company is poised to break even more financial records in 2017. At least part of MJNA’s landmark success can be attributed to its portfolio of subsidiaries and investments, including new IP filings, international licensing and promising findings …

Continue Reading

Posted in Articles| Tagged , , , , |
Medical Marijuana, Inc. (MJNA)

MJNA in Washington on Capitol Hill Side by Side with Americans for Safe Access

Medical Marijuana, Inc.  (MJNA)

Obviously, when you purchase marijuana on the street, you’re not always sure what you’re getting. With different potencies and strains and even the fact that people lace weed with other drugs on occasion, buying marijuana from a dealer is a gamble. Not to mention, purchasing it on the streets is illegal. However, now that medical marijuana is becoming more well known and accepted throughout the country, many are lobbying for safe access to medicinal marijuana to alleviate any issues associated with purchasing marijuana and the regulation of it.

Medical Marijuana, Inc. (OTC: MJNA) are among those who are fighting for the cause. They were the ones to pave the way in the United States as the first publicly traded cannabis company. From April 7th to the 11th, representatives from MJNA attended the 5th Annual National Medical Cannabis Unity Conference at Omni Shoreham Hotel in Washington, DC. Experts, including scientists, …

Continue Reading

Posted in Articles| Tagged , , , |
Medical Marijuana, Inc. (MJNA)

Medical Marijuana, Inc. Positioned Perfectly as New Studies Showcase How CBD Oil is Effective for Treating Epileptic Children

Medical Marijuana, Inc. (MJNA)

According to the Epilepsy Foundation, the incidence of epilepsy is highest in young children and older adults. There are currently 2.2 million people who are believed to have epilepsy in the United States alone, and many of those suffering are children whose symptoms prevent them from going to school and leading normal childhoods. Epileptic seizures can range from mild and infrequent to being characterized by violent and near-constant convulsions. The problem with many existing treatments for epilepsy is that they quite often come with debilitating side effects, are ineffective, or a combination of both. Children are even more severely affected by many of these negative side effects than adult patients, and their young age may limit the treatment options available to them.

Medical marijuana is an increasingly popular treatment option for children and adults with epilepsy. Around the world, there have been promising case studies on the positive effects …

Continue Reading

Posted in Articles| Tagged , , , |

Renowned Doctor Does Study with RSHO-X on LGS (epilepsy) Patients with Incredible Results

MJNA

Lennox-Gastault Syndrome is a severe epileptic disorder that manifests in various forms of seizures. This condition is one of the most severe epilepsies to occur in children. Unfortunately, most LGS patients do not respond well to existing pharmaceutical treatments used to medicate seizures. In many cases, it is impossible to identify the cause of LGS-related seizures, and the seizures themselves are often extremely difficult to manage. LGS may be accompanied by various behavioral and cognitive development issues, and while the condition manifests in childhood, it often continues into adulthood.

Treatment for Lennox-Gastault Syndrome

One of the most difficult aspects of treating LGS in children is the high frequency of seizures that characterizes the syndrome. LGS is also known for being resistant to antiepileptic drugs (AEDs), which can frequently result in debilitating side effects on their own. In a study that ran from January 2016 to February 2017, Dr. Saul …

Continue Reading

Posted in Articles| Tagged , |